Physician profile
Daniel Cohen
NPI 1285692129
$3,701.37
in general payments reported to CMS, 2019-2025
33 companies · $796 in 2025
The $796 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $358 · 2021: $381 · 2022: $535 · 2023: $838 · 2024: $468 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $536.42 | 2020-2025 | |
| Lundbeck LLC | $435.31 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $358.33 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $301.50 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $230.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $194.33 | 2019-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $176.47 | 2022-2024 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $155.83 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Exact Sciences Corporation | $153.36 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $149.95 | 2019-2025 | Evenity, Repatha, Otezla |
| Nestle Healthcare Nutrition INC. | $118.68 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $106.77 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company Ltd. | $91.98 | 2022 | |
| Merck Sharp & Dohme LLC | $84.72 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Sunovion Pharmaceuticals INC. | $77.12 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $74.82 | 2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $63.66 | 2019-2023 | Eliquis |
| Novartis Pharmaceuticals Corporation | $52.30 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.70 | 2019-2021 | |
| Abbvie INC. | $37.55 | 2023-2025 | Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $26.68 | 2021 | |
| Daiichi Sankyo INC. | $25.89 | 2022 | |
| Bioventus LLC | $23.50 | 2019 | |
| Scilex Pharmaceuticals INC. | $22.45 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $20.98 | 2022 | |
| Esperion Therapeutics, INC. | $20.68 | 2020 | |
| Ardelyx, INC. | $19.56 | 2025 | Ibsrela |
| Halozyme INC | $18.00 | 2023 | |
| Abbott Laboratories | $17.97 | 2023 | Freestyle Libre 3 |
| Corium, LLC | $15.42 | 2023 | Azstarys |
| Depuy Synthes Sales INC. | $15.33 | 2019 | |
| Exeltis, USA INC. | $14.18 | 2022 | |
| Janssen Biotech, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.